Ouro Fino Saúde Animal Participações S.A. (BVMF:OFSA3)

Marinus Pharmaceuticals Income Statement

Financials in millions BRL. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1,078	1,025	943.28	1,041	904.99	730.11
Revenue Growth (YoY)	14.69%	8.64%	-9.40%	15.04%	23.95%	17.84%
Cost of Revenue	525.31	507.11	511.55	513.03	457.73	356.12
Gross Profit	552.63	517.69	431.73	528.08	447.26	373.99
Selling, General & Admin	316.09	290.58	274.08	284.47	244.23	217.38
Research & Development	49.45	49.45	59.7	69.34	58.93	39.67
Other Operating Expenses	-0.71	-7.87	-4.74	1.15	-0.28	-5.64
Operating Expenses	364.83	332.16	329.04	354.96	302.88	251.41
Operating Income	187.81	185.53	102.7	173.12	144.38	122.58
Interest Expense	-31.63	-31.49	-37.07	-37.45	-19.63	-13.91
Interest & Investment Income	29.16	29.16	27.78	17.09	7.53	2.99
Currency Exchange Gain (Loss)	-0.47	-0.47	3	-4.69	0.11	-11.28
Other Non Operating Income (Expenses)	-12.32	-6.93	-20.47	-5.21	-3.43	13.92
EBT Excluding Unusual Items	172.54	175.8	75.94	142.86	128.96	114.3
Merger & Restructuring Charges	-	-	-	1.67	-	-
Impairment of Goodwill	-	-	-18.09	-	-	-
Gain (Loss) on Sale of Assets	1.49	1.49	0.79	3.01	2.55	0.21
Asset Writedown	-3.08	-3.08	-0.88	-0.48	-5.82	-20.66
Legal Settlements	2.9	2.9	-	-	-	-
Other Unusual Items	-	-	-3.5	-	-	-
Pretax Income	173.85	177.1	54.25	147.06	125.69	93.84
Income Tax Expense	42.98	42.77	104.23	16.41	11.73	4.12
Earnings From Continuing Operations	130.88	134.33	-49.98	130.66	113.96	89.71
Net Income to Company	130.88	134.33	-49.98	130.66	113.96	89.71
Minority Interest in Earnings	0	0	0	0.01	0.01	0.01
Net Income	130.88	134.33	-49.98	130.66	113.96	89.72
Net Income to Common	130.88	134.33	-49.98	130.66	113.96	89.72
Net Income Growth	144.29%	-	-	14.65%	27.02%	93.87%
Shares Outstanding (Basic)	54	54	54	54	54	54
Shares Outstanding (Diluted)	54	54	54	54	54	54
Shares Change (YoY)	-	-	-	-0.27%	-0.06%	-
EPS (Basic)	2.43	2.50	-0.93	2.43	2.11	1.66
EPS (Diluted)	2.43	2.50	-0.93	2.43	2.11	1.66
EPS Growth	144.28%	-	-	14.97%	27.10%	93.87%
Free Cash Flow	-0.98	56.14	165.38	37.62	-9.41	96.69
Free Cash Flow Per Share	-0.02	1.04	3.08	0.70	-0.17	1.79
Dividend Per Share	0.577	0.577	0.613	0.197	-	-
Dividend Growth	-5.99%	-5.99%	211.80%	-	-	-
Gross Margin	51.27%	50.52%	45.77%	50.72%	49.42%	51.22%
Operating Margin	17.42%	18.10%	10.89%	16.63%	15.95%	16.79%
Profit Margin	12.14%	13.11%	-5.30%	12.55%	12.59%	12.29%
Free Cash Flow Margin	-0.09%	5.48%	17.53%	3.61%	-1.04%	13.24%
EBITDA	210.25	207.4	126.68	195.51	164.05	140.97
EBITDA Margin	19.50%	20.24%	13.43%	18.78%	18.13%	19.31%
D&A For EBITDA	22.44	21.87	23.98	22.39	19.67	18.4
EBIT	187.81	185.53	102.7	173.12	144.38	122.58
EBIT Margin	17.42%	18.10%	10.89%	16.63%	15.95%	16.79%
Effective Tax Rate	24.72%	24.15%	192.12%	11.15%	9.34%	4.40%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.